Key points are not available for this paper at this time.
Recent studies have reported that microRNA-155 (miR-155) is linked to the clinical outcomes of many tumors. However, its role in prognosis of gliomas remains unclear. This meta-analysis aims to evaluate the prognostic value of miR-155 in the survival of patients with gliomas. Hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) were pooled with random effects or fixed effects models on the basis of heterogeneity. Subgroup analysis and sensitivity analysis were performed to elucidate the possible confounding factors and investigate the source of heterogeneity. In addition, we assessed publication bias using the Begg's funnel plots, Egger's test, and Begg's test. Only non-laboratory studies were considered for our analysis. 9 studies from 6 articles containing 1259 glioma patients were included. The pooled HR of elevated miR-155 for OS in patients with gliomas was 1.40 (95%CI 1.19-1.63, P < 0.001) (I-squared = 52.4%, P = 0.032) suggesting that miR-155 might be a promising biomarker for the prognosis of gliomas in future clinical applications.
Zhou et al. (Fri,) studied this question.